Penketh P G, Shyam K, Baumann R P, Remack J S, Brent T P, Sartorelli A C
Department of Pharmacology and Developmental Therapeutics Program, Cancer Center, Yale University School of Medicine, New Haven, CT 06520, USA.
Cancer Chemother Pharmacol. 2004 Apr;53(4):279-87. doi: 10.1007/s00280-003-0740-7. Epub 2003 Dec 24.
To investigate the interaction of the electrophilic species generated by the decomposition of the antineoplastic prodrug 1,2-bis(methylsulfonyl)-1-(2-chloroethyl)-2-[(methylamino)carbonyl]hydrazine (VNP40101M) on the ability of O(6)-alkylguanine-DNA alkyltransferase (AGT) to repair alkylated O(6)-chloroethylguanine and/or N(1),O(6)-ethanoguanine DNA lesions.
The contributions of inhibitory electrophilic species generated from VNP40101M towards AGT was assessed using analogues that selectively generated either the chloroethylating or the carbamoylating components of VNP40101M. The activity of AGT was determined from the inhibition of crosslink formation from O(6)-chloroethylguanine and/or N(1),O(6)-ethanoguanine lesions. The half-lives of sulfonylhydrazine derivatives and isocyanates were measured using an acidification assay which gives a change in absorbance proportional to the release or consumption of small quantities of protons.
Both of the reactive components produced by VNP40101M directly inactivated cloned human AGT; the carbamoylating moiety (IC(50) about 13 micro M) was approximately seven- to eight-fold more potent than the alkylating component(s) (IC(50) about 100 micro M). These inhibitory actions were moderated by the addition of naked T5 bacteriophage DNA. Thus, AGT bound to DNA was markedly more resistant than free AGT to these electrophilic species. DNA also blocked the spontaneous loss of AGT activity which occurred upon incubation of this protein under mild conditions.
The reaction of AGT with the methyl isocyanate generated from the decomposition of VNP40101M increased the net number of crosslinks generated by VNP40101M compared to a sulfonylhydrazine prodrug that formed the equivalent alkylating species in the absence of the cogeneration of methyl isocyanate. These actions may be of significance to the antineoplastic activity of VNP40101M.
研究抗肿瘤前药1,2 - 双(甲基磺酰基)-1 - (2 - 氯乙基)-2 - [(甲氨基)羰基]肼(VNP40101M)分解产生的亲电物质对O(6)-烷基鸟嘌呤 - DNA烷基转移酶(AGT)修复烷基化O(6)-氯乙基鸟嘌呤和/或N(1),O(6)-乙撑鸟嘌呤DNA损伤能力的影响。
使用选择性产生VNP40101M的氯乙基化或氨基甲酰化成分的类似物,评估VNP40101M产生的抑制性亲电物质对AGT的作用。通过抑制O(6)-氯乙基鸟嘌呤和/或N(1),O(6)-乙撑鸟嘌呤损伤形成交联来测定AGT的活性。使用酸化测定法测量磺酰肼衍生物和异氰酸酯的半衰期,该方法产生的吸光度变化与少量质子的释放或消耗成比例。
VNP40101M产生的两种反应性成分均直接使克隆的人AGT失活;氨基甲酰化部分(IC(50)约为13 μM)的活性比烷基化部分(IC(50)约为100 μM)强约七至八倍。添加裸露的T5噬菌体DNA可减轻这些抑制作用。因此,与游离AGT相比,与DNA结合的AGT对这些亲电物质的抗性明显更强。DNA还阻止了在温和条件下孵育该蛋白时AGT活性的自发丧失。
与在不联产甲基异氰酸酯的情况下形成等效烷基化物质的磺酰肼前药相比,AGT与VNP40101M分解产生的甲基异氰酸酯的反应增加了VNP40101M产生的交联净数量。这些作用可能对VNP40101M的抗肿瘤活性具有重要意义。